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Abstract: Routine diagnostic screening of inborn errors of metabolism (IEM) is currently performed by
different targeted analyses of known biomarkers. This approach is time-consuming, targets a limited
number of biomarkers and will not identify new biomarkers. Untargeted metabolomics generates a
global metabolic phenotype and has the potential to overcome these issues. We describe a novel, single
platform, untargeted metabolomics method for screening IEM, combining semi-automatic sample
preparation with pentafluorophenylpropyl phase (PFPP)-based UHPLC- Orbitrap-MS. We evaluated
analytical performance and diagnostic capability of the method by analysing plasma samples of 260
controls and 53 patients with 33 distinct IEM. Analytical reproducibility was excellent, with peak area
variation coefficients below 20% for the majority of the metabolites. We illustrate that PFPP-based
chromatography enhances identification of isomeric compounds. Ranked z-score plots of metabolites
annotated in IEM samples were reviewed by two laboratory specialists experienced in biochemical
genetics, resulting in the correct diagnosis in 90% of cases. Thus, our untargeted metabolomics
platform is robust and differentiates metabolite patterns of different IEMs from those of controls. We
envision that the current approach to diagnose IEM, using numerous tests, will eventually be replaced
by untargeted metabolomics methods, which also have the potential to discover novel biomarkers
and assist in interpretation of genetic data.
Keywords: metabolomics; inborn errors of metabolism; LC-MS; HRAM-MS; Orbitrap; PFPP; IEM;
organic aciduria; urea cycle defects; PKU
1. Introduction
Routine diagnostic testing for inborn errors of metabolism (IEM) in clinically selected individuals
is currently performed by targeted analysis of known biomarkers [1]. In most laboratories, specific
groups of metabolites, such as organic acids, amino acids and acylcarnitines, are analyzed by dedicated
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platforms (e.g., GC-MS, HPLC-DAD/UV and LC-MS/MS). These dedicated assays require multiple
preparations of different types of samples, such as urine, plasma or cerebrospinal fluid. This diagnostic
process is laborious, time-consuming, expensive, and delays diagnosis and, consequently, specific
treatment. Targeted assays including multiple metabolite groups have been developed to address
these issues [2,3]. Targeted assays are optimized for the physicochemical properties of the biomarkers
and the matrices of the samples, which, in general, result in reliable (semi-) quantitative analyses.
As a consequence, a dedicated assay can never provide a comprehensive overview of the patient’s
metabolome, as (i) a limited number of dedicated tests will not determine those known biomarkers that
require alternative platforms and (ii) targeted assays fail to identify novel biomarkers and new IEM.
Diagnostic use of untargeted metabolomics has only very recently become feasible, due to recent
advances in UHPLC and high-resolution accurate mass spectrometry (HRAM)-MS. Especially the
ultra-high resolution of Orbitrap-MS enables the accurate detection of molecular ions (<1 ppm mass
deviations) and the resolution of their fine isotope patterns, allowing unsurpassed specificity. As a
consequence, untargeted metabolomics have become a promising technique, with the potential to
overcome the disadvantages of targeted assays mentioned above [4–7]. It offers the determination of
hundreds to thousands of small molecules in a single experiment, allowing the detection of numerous
molecules—substrates, intermediates and final products—in metabolic pathways.
Only few untargeted metabolomics-based methods to screen for IEM have been published.
The first published method applied GC-MS and LC-high resolution MS run in parallel [8]. The
second [9] and the third [10] methods used LC-QTOF/MS. The fourth metabolomics assay is based on
Orbitrap-MS without using chromatographic separation [11]. Although applications of untargeted
metabolomics in IEM screening are emerging, they are still in an exploratory phase and various
challenges need to be addressed, such as high-throughput sample preparation, identification and
separation of isobaric and isomeric molecular species, and data-processing.
Here, we describe a powerful novel single platform untargeted metabolomics method that we
developed for screening of IEM. We illustrate that pentafluorophenylpropyl phase-based UHPLC
coupled to ultra-high mass resolution Orbitrap-MS enhances separation of isobaric and isomeric
metabolites. We describe the reproducibility of test results and evaluate the diagnostic capacity of the
method by analyzing plasma samples of 53 patients with 33 distinct IEM in different metabolic pathways.
2. Results
2.1. Analytical Performance
Plasma samples were analyzed in the positive as well as in the negative ionization mode in eight
independent batches, including a total of 260 control samples and 53 IEM patient samples. More than
2 × 106 peaks were detected in the raw data of each sample. Each batch was separately processed,
resulting in the detection of more than 17,256 (range: 17,256–26,775) compound ions (i.e., an analytical
feature with a specific m/z ratio, intensity, retention time and its corresponding isotope pattern signals).
To explore potential IEM disease markers, the >17,250 compound ions detected in each plasma sample
were matched against 339 clinically relevant biomarkers included in our in-house database. On average,
178 metabolite annotations were made in each of the 16 experiments (range 140–244). Mass accuracy of
these annotations was always within 3 ppm, while 78.6% were within 1 ppm.
2.2. Retention Time Stability
To investigate the chromatographic stability of the LC method, we monitored within-batch and
between-batch retention time (RT) variation of 17 stable isotope-labeled standards, which were added
to the samples. Within batch RT variation was never higher than 1.12% for the positive ion mode and
0.37% for the negative ion mode, while the median CV of within batch variation was 0.22% (all plasma
samples and QC samples, N = 29–166). Median and range data for all internal and external standards
of all batches are shown in supplementary materials S1. Between batch RT variation was within
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2% (all plasma samples and QC samples), except for [D10]-isoleucine (3.8%, N = 1011), [D2]-uridine
(4.7%, N = 1011), [D3]-methylmalonic acid (5.3%, N = 504), and [D4]-tyrosine (5.4%, N = 1011), which
were all eluting between 1.70–2.80 min. This larger variation probably relates to the use of two
analytical columns (although manufactured with core-shell particles from the same batch) during
the experiments, since RT variation between different batches analyzed on one column was always
within 2%. Between-batch RT variation data for all internal and external standards are shown in
supplementary materials S2.
2.3. Variation in Peak Area
Median within-batch CV values of peak areas of internal and external standards in all plasma
and QC samples were 7–19% (range 4–30%, N = 29–83). Relatively large variations were observed for
[D3]-tetradecanoylcarnitine and [D3]-hexadecanoylcarnitine, with median CVs over the eight batches
of 19.0% and 19.4%, respectively (range 13.1–30.3%, N = 29–83). Within-batch median CVs and ranges
for all internal and external standards in both ion modes are shown in supplementary materials S3.
Median between-batch variation of all standards in all plasma and QC samples was 27% (range 17–68%,
N = 504–1011). Between-batch median CVs of all internal and external standards in all samples are
shown in supplementary materials S4.
To obtain more information regarding the reproducibility of peak areas across a chromatographic
run, we monitored peak areas of metabolites that were consistently annotated in all analyses of the QC
sample across the eight batches (supplementary materials S8). Within-batch CVs were determined
per metabolite and binned by retention time (bin width: 1 min), covering the whole chromatogram
for all eight batches. For each batch, this resulted in 11 bins and 10 bins containing a total of 119 and
87 metabolites, for the positive and negative ion mode, respectively. First, we reviewed each bin in
the eight batches separately, i.e., 88 bins for the positive ion mode and 80 bins for the negative ion
mode. Median CV of variation in peak area in the positive ion mode was <30% for 73/88 bins (83%)
and 66/88 bins (75%) had a median CV <20%. In the negative ion mode, 73/80 bins (91%) had a median
CV <30%, while in 62/80 bins (78%) median CV was <20%. The largest variation was observed near
the end of the chromatogram in bins 8–9, 9–10 and 10–11 min (supplementary materials S5). Next, we
reviewed median CVs across all batches for each bin (see Figure 1). A constant low variation in the
peak areas measured in a bin across batches suggests a stable LC-MS method. Only bins 8–9, 9–10
and 10–11 min in the positive ion mode showed a median CV >20%, while in the negative ion mode a
median variation >20% was observed in bins 6–7, 8–9 and 9–10 min (Figure 1). Overall, 182 of the 206
(88%) metabolites annotated had a median CV <20%.
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We selected pentafluorophenylpropyl (PFPP) phase-based chromatography, because PFPP, as a 
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retention time variation and required stabilization times, compared to HILIC [12–16]. An example of 
compounds that are separated by our LC-method is the isomeric group N-acetylisoleucine, 
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2.4. Separation of Isobaric and Isomeric Species
Correct annotation of features is crucial in the diagnostics of IEM, because misidentification
or lack of identification can result into false positive or false negative results. In this respect, it is
challenging to make the correct annotation of isobaric and isomeric species. Using our Orbitrap-MS,
a resolution of 140,000 is feasible while maintaining adequate data sampling frequency (1.8 scans/s).
To determine the ability to separate isobaric ions by using only mass spectrometry, we identified
1608 combinations of isobaric ions derived from metabolites present in our in-house database, which
required a resolution >40,000 for separation. In the ESI(+)-mode 1032 out of 1608 combinations (64%)
could be baseline-separated by acquiring the data at a resolution of 140,000. This included, for example,
serine[K+] and cysteine[Na+], that co-elute in our LC-method. In the ESI(-)-mode, 1010 out of 1608
combinations (63%) could be resolved by acquiring the data at a resolution of 140,000 (detailed data
available on request).
To achieve correct annotation of isomeric compounds, chromatographic separation is required.
We selected pentafluorophenylpropyl (PFPP) phase-based chromatography, because PFPP, as a
stationary phase, shows better retention for small polar compounds, such as organic acids and
amino acids, compared to traditional C18-based chromatography and is more stable in terms of
retention time variation and required stabilization times, compared to HILIC [12–16]. An example
of compounds that are separated by our LC-method is the isomeric group N-acetylisoleucine,
N-acetylleucine, isohexanoylglycine and hexanoylglycine (C8H15NO3). Separation of these isomers
is required to distinguish aminoacylase I deficiency from medium chain acyl-CoA dehydrogenase
deficiency. Figure 2 clearly shows separation of N-acetylisoleucine and N-acetylleucine in a plasma
sample of a patient with aminoacylase I deficiency, while hexanoylglycine and isohexanoylglycine
peaks are present at different retention times in a plasma sample of a patient with medium
chain acyl-CoA dehydrogenase deficiency. Other examples of compounds that can be separated
by our LC method using PFPP chromatography are the isomeric pairs isoleucine/leucine and
betaine/valine (see supplementary material S6), as well as 2-hydroxybutyric acid/3-hydroxybutyric
acid/4-hydroxybutyric acid (C4H8O3), glutaric acid/ethylmalonic acid/methylsuccinic acid (C5H8O4)
and tiglylglycine/3-methylcrotonylglycine (C7H11NO3) (data not shown).
2.5. Data Analysis and IEM Detection
We have studied plasma samples of 53 patients covering 33 distinct IEM to evaluate our
UHPLC-Orbitrap-MS platform and data processing pipeline. We investigated the ability to (1) detect
metabolites relevant to IEM and (2) to produce metabolite signatures that can be interpreted to assign
a diagnosis. Z-scores of annotated metabolites were calculated using 15 age - and sex-matched
control samples originating from the same batch as the patient samples (Table 1). Ranked z-score
plots (metabolite with highest z-score at the top), representing metabolic signatures of the 53 patient
samples analyzed, were reviewed in a blinded fashion and independently by two laboratory specialists
experienced in clinical biochemical genetics to assign the most likely diagnosis. The z-score plot
obtained for a hyperargininemia sample is shown in Figure 3 as an example. In 95 of the 106 reviews
(90%), the correct diagnosis was achieved. Two diagnoses remained undetected: alkaptonuria and
mevalonic aciduria. The known diagnostic biomarkers for these diseases, homogentisic acid and
mevalonic acid, were found, but the levels were not significantly different compared to the controls
(Table 1). Surprisingly, the urinary homogentisic acid level of the alkaptonuria patient sampled on
the same day was strongly elevated (3074 mmol/mol creatinine; reference values <5). Diagnoses
were incorrect in some of the cases reviewed for the following IEM: carbamylphosphate synthase I
deficiency (two out of four reviews), ornithine transcarbamylase deficiency (1/4), homocystinuria (1/6),
tyrosinemia type I (1/4), carnitine transporter deficiency (1/2) and 2-methyl-3-hydroxybutyryl-CoA
dehydrogenase deficiency (1/2).
To highlight the unique features of untargeted metabolomics, which may result in the discovery
of new biomarkers for diagnosis and therapy monitoring, we present a case of hyperargininemia. In
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the traditional targeted diagnostic process, hyperargininemia would be diagnosed if plasma levels
of arginine are strongly elevated together with elevated plasma levels of glutamine and citrulline
and high levels of urinary orotic acid [18]. We performed untargeted metabolomics on a plasma
sample of a hyperargininemia patient treated by dietary protein restriction. As expected, arginine
was only marginally increased, due to treatment, with a z-score of 2.4 and p-value > 0.05 (Figure 3,
Table 1). Despite the treatment, we detected several elevated features, which were putatively annotated
as 2-oxoarginine, N-acetylarginine, argininic acid, homoarginine and 4-guanidinobutyric acid by
the Human Metabolite Database (HMDB). These metabolites have been reported previously in
hyperargininemia patients [19–22]. Inclusion of these biomarkers in the panel of IEM metabolites
resulted in high z-scores for N-acetylarginine, homoarginine and 4-guanidinobutyric acid in addition
to orotic acid, a well-established biomarker of several urea cycle defects (Figure 3, Table 1). This
example shows the strength of untargeted metabolomics analyses. The additional three biomarkers
help to appoint the diagnosis hyperargininemia in this sample. Argininic acid and 2-oxoarginine
remained undetected during the automated raw data analysis, but manual review of the raw data
revealed elevated levels compared to controls. Argininic acid was not peak-picked in either ion mode
by Progenesis QI, while 2-oxoarginine was not peak-picked in the negative ion mode and its peak
incorrectly deconvoluted in the positive ion mode (the [M+H] adduct of 2-oxoarginine was annotated
as the [M-H2O+H] adduct of 4-hydroxycitrulline).Metabolites 2019, 9, x 5 of 22 
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Figure 2. Separation of isomeric compounds using pentafluorophenylpropyl-based UHPLC. Panel (A)
XIC (mass tolerance: 1 ppm, ionization: ESI(-)) of 172.09792 m/z in an aminoacylase I deficiency sample
showing peaks of N-acetylisoleucine (RT: 4.533 min) and N-acetylleucine (RT: 4.628 min). Panel (B): XIC
(mass tolerance: 1 ppm, ionization: ESI(-)) of 172.09792 m/z in a medium chain acyl-CoA dehydrogenase
deficiency sample showing peaks of N-acetylleucine (RT: 4.598 min), isohexanoylglycine (RT: 4.686 min)
and hexanoylglycine (RT: 4.752 i ).
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Table 1. Method evaluation for 33 distinct inborn errors of metabolism (IEM).
Inborn Error of Metabolism a Z-Score b p-Value c ID d
2-Methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency (N = 1)
2-Methyl-3-hydroxybutyric acid [↑] (+/−) NF NF -
Tiglylglycine [↑] (−) 7.0 * 2.99 × 10−3 2b
3-Methylcrotonyl-CoA-carboxylase deficiency (N = 1)
3-Hydroxyisovaleric acid [↑] (+/−) NF NF -
3-Methylcrotonylglycine [↑] (−) 33.7 * 1.50 × 10−2 2b
3-Hydroxyisovalerylcarnitine [↑] (+) 1811.7 * 4.35 × 10−3 2b
Adenylosuccinate lyase deficiency (N = 1)
SAICAR [↑] (+/−) NF NF -
Succinyladenosine [↑] (−) 57.2 * 2.80 × 10−3 2b
Alkaptonuria (N = 1)
Homogentisic acid [↑] (+) 0.6 3.78 × 10−1 2b
Alpha-Methylacyl-CoA racemase deficiency (N = 2)
Pristanoyl-carnitine [↑] (+/−) NF NF -
Phytanoyl-carnitine [↑] (+/−) NF NF -
Dihydroxycholestanoic acid + Gly [↑] (−) INF/INF <1.1 × 10−16/<1.1 × 10−16 2b
Dihydroxycholestanoic acid + Tau [↑] (−) 121.5 */34.1 * 1.95 × 10−3/1.51 × 10−2 2b
Trihydroxycholestanoic acid + Gly [↑] (−) 462.6 */386.6 * 1.70 × 10−3/1.45 × 10−2 2b
Trihydroxycholestanoic acid + Tau [↑] (−) 500.4 */326.5 * 9.07 × 10−4/1.70 × 10−2 2b
Aminoacylase I deficiency (N = 1)
N-Acetylalanine [↑] (−) 8.7 * 1.74 × 10−2 2b
N-Acetylarginine [↑] (−) 0.4 1.69 × 10−1 2b
N-Acetylglutamic acid [↑] (−) 362.9 * 1.19 × 10−2 2b
N-Acetylglycine [↑] (−) 8.9 * 1.06 × 10−2 2b
N-Acetylleucine [↑] (−) 23.0 * 1.31 × 10−2 2b
N-Acetylmethionine [↑] (−) 644.7 * 8.44 × 10−3 2b
N-Acetylserine [↑] (−) NF NF -
N-Acetylthreonine [↑] (+) 1259.4 * 1.31 × 10−2 2b
Arginase deficiency (N = 1)
2-Oxoarginine [↑] (−) NF e NF -
4-Guanidinobutyric acid [↑] (−) 25.7 * 1.18 × 10−2 2b
Arginine [↑] (+) 2.4 5.14 × 10−2 1
Glutamine + Glutamic acid [↑] (−) −0.1 7.51 × 10−1 1
Guanidinoacetic acid [↑] (−) 2.7 * 6.08 × 10−6 1
Homoarginine [↑] (+) 9.7 * 3.45 × 10−2 2b
N-Acetylarginine [↑] (−) 137.2 * 3.20 × 10−4 2b
Orotic acid [↑] (−) 32.4 * 5.85 × 10−4 2b
Uracil [↑] (−) 5.7 * 4.02 × 10−3 1
Uridine [↑] (−) 3.1 * 1.60 × 10−6 1
Argininic acid [↑] (+/−) NF e NF -
Argininosuccinic aciduria (N = 3)
Arginine [↓] (+) −0.9 *–−0.3 2.01 × 10−1–2.98 × 10−2 1
Argininosuccinic acid [↑] (−) 4797 *–13,725 * 2.96 × 10−2–5.40 × 10−3 2b
Citrulline [↑] (−) 10 *–32 * 4.87 × 10−3–2.83 × 10−4 1
Cytidine [↑] (−) 3580 */2.1 */NF 9.78 × 10−3/7.33 × 10−6/NF 1
Glutamine + Glutamic acid [↑] (+) 2.2 */−1.8 */NF 6.99 × 10−3/7.51 × 10−6/NF 1
Homocitrulline [↑] (+) 1.7 *–4.5 6.69 × 10−4–2.81 × 10−5 2b
N-Acetylcitrulline [↑] (−) 6.2 *–42.7 * 8.23 × 10−3–9.02 × 10−4 2b
Orotic acid [↑] (−) 0.1/−0.5/NF 6.61 × 10−1/1.08 × 10−1/NF 2b
Uracil [↑] (−) −0.7 */−1.9 * /NF 1.89 × 10−2/5.20 × 10−6/NF 1
Uridine [↑] (−) −0.4–3.4 * 1.70 × 10−1–1.06 × 10−3 1
Beta-ketothiolase deficiency (N = 2)
2-Methyl-3-hydroxybutyric acid [↑] (−) 5.8 */15.7 * 2.66 × 10−2/1.03 × 10−3 4
2-Methylacetoacetic acid [↑] (−) 0.5/NF 5.84 × 10−1/NF 4
Tiglylcarnitine [↑] (+) 0.3/NF 0.726/NF 2b
Tiglylglycine [↑] (−) 190 */217 * 1.23 × 10−2/7.96 × 10−5 2b
Beta-mannosidosis (N = 1)
GlcNAc-Man [↑] (−) 383.9 * 5,73 × 10−3 2b
Carbamoyl phosphate synthetase I deficiency (N = 2)
Glutamine + Glutamic acid [↑] (+) 4.7 */0.59 6.43 × 10−5/1.4 × 10−1 1
Citrullinemia type I (N = 1)
Arginine [↓] (+) 0.5 4.06 × 10−1 1
Citrulline [↑] (+) 128.7 * 3.64 × 10−3 1
Citrulline lactam [↑] (+) 202,9 9.13 × 10−2 4
Glutamine + Glutamic acid [↑] (+) −2.4 * 3.28 × 10−2 1
N-Acetylcitrulline [↑] (−) 335.2 * 3.77 × 10−3 2b
Orotic acid [↑] (−) 0.3 3.64 × 10−1 2b
Uracil [↑] (−) 0.1 8.50 × 10−1 1
Uridine [↑] (−) 1.4 * 6.41 × 10−3 1
Glutamate formiminotransferase deficiency (N = 1)
Formiminoglutamic acid [↑] (+) 2031.0 * 7.13 × 10−3 2b
Hydantion-5-propionic acid [↑] (−) 12.0 * 2.24 × 10−5 2b
Glutaric aciduria I (N = 2)
3-Hydroxyglutaric acid [↑] (−) 2.1 */NF 5.49 × 10−5/NF 4
Glutarylcarnitine [↑] (+) 317.4 */338.6 * 5.57 × 10−3/4.72 × 10−3 1
Glutaric acid [↑] (−) 0.7/2.5 * 3.05 × 10−5/2.16 × 10−7 1
Glutarylglycine [↑] (−) 228.8 */513.4 * 2.90 × 10−3/9.19 × 10−4 4
Glutaric aciduria II (N = 2)
2-Hydroxyglutaric acid [↑] (−) 39.1 */73.7 * 6.27 × 10−3/2.23 × 10−3 4
3-Hydroxyglutaric acid [↑] (−) 2.9 */NF 2,15 × 10−5/NF 4
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Table 1. Cont.
Inborn Error of Metabolism a Z-Score b p-Value c ID d
Ethylmalonic acid [↑] (−) 1.2/53.6 * 1.61 × 10−1/5.02 × 10−3 1
Glutaric acid [↑] (−) 1.8 */2.1 * 9.31 × 10−6/3.03 × 10−5 1
Hexanoylglycine [↑] (−) 391.2 */1797.4 * 6.37 × 10−3/1.05 × 10−3 2b
Isobutyrylglycine [↑] (−) 16.4 */NF 4,56 × 10−3/NF 2b
Isovaleryglycine [↑] (−) 51.5 */1.1 * 7.78 × 10−3/3.37 × 10−2 2b
(Iso)butyrylcarnitine [↑] (+) 30.2 */110.2 * 5.65 × 10−4/8.95 × 10−4 1
Isovalerylcarnitine [↑] (+) 189.6 */34.1 * 9.08 × 10−4/3.06 × 10−3 1
Glutarylcarnitine [↑] (+) 28.7 */85.9 * 2.37 × 10−3/9.32 × 10−4 2b
Hexanoylcarnitine [↑] (+) 124.5 */184.6 * 3.24 × 10−3/9.02 × 10−3 1
Octanoylcarnitine [↑] (+) 101.8 */123.1 * 2.71 × 10−3/6.21 × 10−4 1
Decanoylcarnitine [↑] (+) 72.0 */70.4 * 1.73 × 10−3/1.47 × 10−3 1
Dodecanoylcarnitine [↑] (+) 0.9/80.0 * 7.21 × 10−2/1.01 × 10−2 1
Tetradecanoylcarnitine [↑] (+) 125.7/101.7 * 1.51 × 10−1/5.78 × 10−3 1
Tetradecenoylcarnitine [↑] (+) 100.8 */61.9 * 4.70 × 10−2/2.82 × 10−4 1
Hexadecanoylcarnitine [↑] (+) 6.1/9.9 * 1.99 × 10−1/1.97 × 10−2 1
Hexadecenoylcarnitine [↑] (+) 189.3/130.2 * 1.16 × 10−1/5.25 × 10−3 1
Octadecanoylcarnitine [↑] (+) 4.2/4.5 1.80 × 10−1/1.43 × 10−1 1
Oleoylcarnitine [↑] (+) 7.5/11.8 * 1.87 × 10−1/4.68 × 10−2 1
Linoleoylcarnitine [↑] (+) 13.9/21.5 * 1.54 × 10−1/1.09 × 10−3 1
Homocystinuria (CBS deficiency) (N = 3)
Cysteinyl-homocysteine [↑] (+/−) NF NF -
Homocysteine [↑] (+) 0.5–1.2 * 9.93 × 10−2–4.93 × 10−3 1
Homocystine [↑] (+/−) NF NF -
Methionine + Methionine sulfoxide [↑] (+) 6.5 *–55.1 * 5.01 × 10−3–2.71 × 10−4 1
Homocysteic acid [↑] (+/−) NF NF -
Isovaleric acidemia (N = 1)
3-Hydroxyisovaleric acid [↑] (−) −1.8 * 8.52 × 10−5 1
4-Hydroxyisovaleric acid [↑] (−) NF NF -
Isovalerylcarnitine [↑] (+) 69.2 * 1.40 × 10−4 1
Isovaleryglycine [↑] (−) 159.9 * 8.82 × 10−4 1
Long-chain-3-hydroxyacyl CoA dehydrogenase deficiency (N = 2)
3-Hydroxyadipic acid [↑] (−) NF NF -
3-Hydroxydecanedioic acid [↑] (−) NF NF -
3-Hydroxytetradecenoylcarnitine [↑] (+) 11.7 */19.6 * 8.84 × 10−3/2.56 × 10−3 2b
3-Hydroxytetradecanoylcarnitine [↑] (+) 37.9 */16.9 * 1.90 × 10−2/3.54 × 10−2 2b
3-Hydroxyhexadecenoylcarnitine [↑] (+) 142.4 */61.6 * 2.39 × 10−2/2.94 × 10−2 2b
3-Hydroxyhexadecanoylcarnitine [↑] (+) 402.1/67.3 8.01 × 10−2/1.62 × 10−1 2b
3-Hydroxyoleoylcarnitine [↑] (+) 1141.8/149.3 7.30 × 10−2/1.56 × 10−1 2b
3-Hydroxyoctadecanoylcarnitine [↑] (+) 754.6/35.2 9.32 × 10−2/1.93 × 10−1 2b
Sebacic acid [↑] (−) 6.1 */2.3 * 1.92 × 10−2/5.01 × 10−3 4
Suberic acid [↑] (−) 2.2/1.6 * 2.06 × 10−1/3.44 × 10−2 4
Lysinuric protein intolerance (N = 2)
Arginine [↓] (+) −1.5 */2.4 * 6.40 × 10−3/3.04 × 10−6 1
Glutamine + Glutamic acid [↑] (+) 3.2 */6.4 * 3.46 × 10−4/1.83 × 10−13 1
Lysine [↓] (+) −1.6 */−1.9 * 2.50 × 10−5/1.38 × 10−5 1
Ornithine [↓] (+) −2.1 */1.1 5.87 × 10−1/3.41 × 10−6 1
Orotic acid [↑] (−) 4.0 */NF 3.27 × 10−2/NF 4
Malonyl-CoA decarboxylase deficiency (N = 1)
Malonylcarnitine [↑] (+) 132.7 * 9.84 × 10−3 2b
Malonic acid [↑] (−) 0.1 8.39 × 10−1 1
Maple syrup urine disease (N = 2)
(allo)Isoleucine [↑] (+) 3.1 */17.7 * 3.91 × 10−3/4.95 × 10−3 1
2-Hydroxy-3-methylbutyric acid [↑] (−) NF NF -
2-Hydroxy-3-methylvaleric acid [↑] (−) NF NF -
2-Hydroxy-4-methylvaleric acid [↑] (−) NF NF -
2-Keto-3-methylbutyric acid [↑] (−) NF NF -
2-Keto-3-methylvaleric acid [↑] (−) −1.9 */25.5 * 2.95 × 10−6/4.52 × 10−2 4
2-Keto-4-methylvaleric acid [↑] (−) −2.0 */1.4 1.45 × 10−6/1.48 × 10−1 4
Leucine [↑] (+) 3.1 */22.1 * 6.85 × 10−3/4.25 × 10−3 1
Valine [↑] (+) 1.2/5.2 * 5.61 × 10−2/4.63 × 10−3 1
Medium chain acyl-CoA dehydrogenase deficiency (N = 4)
5-Hydroxyhexanoic acid [↑] (−) NF NF -
7-Hydroxyoctanoic acid [↑] (−) NF NF -
Decenoylcarnitine [↑] (+) 8.8 *–45.1 * 4.24 × 10−3–6.42 × 10−5 1
Hexanoylcarnitine [↑] (+) 11.2 *–54.3 * 2.12 × 10−3–1.11 × 10−5 1
Octanoylcarnitine [↑] (+) 25.5 *–60.7 * 4.63 × 10−3–1.87 × 10−3 1
Decenedioic acid [↑] (−) NF NF -
Hexanoic acid/Trans-cyclohexan × 10-1,2-diol [↑]
(−) −0.4–1.9 6.69 × 10−1–2.51 × 10−1 1
Hexanoylglycine [↑] (−) 29.3 *–125.4 * 1.23 × 10−2–6.83 × 10−3 2b
Octanoic acid [↑] (−) 26.5 *–61.5 * 9.37 × 10−3–2.57 × 10−3 4
Octanoylglycine [↑] (−) 169.5 *–1281.0 9.76 × 10−3–2.02 × 10−3 2b
Phenylpropionylglycine [↑] (−) 220.0 *–1629.8 * 9.89 × 10−3–2.44 × 10−3 2b
Sebacic acid [↑] (−) 0.0–−0.3 9.94 × 10−1–3.90 × 10−1 4
Suberic acid [↑] (−) −0.1–0.6 * 8.34 × 10−1–3.44 × 10−2 4
Suberylglycine [↑] (−) 61.3 *–350.5 * 1.90 × 10−2–3.83 × 10−3 2b
Undecanoylcarnitine [↑] (+) −0.6–0.1 7.88 × 10−1–9.32 × 10−2 4
Heptanoylcarnitine [↑] (+) 3.1 *–10.7 * 2.13 × 10−2–6.56 × 10−4 4
Nonanoylcarnitine [↑] (+) 53.7 *–110.5 * 4.37 × 10−3–8.91 × 10−4 4
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Table 1. Cont.
Inborn Error of Metabolism a Z-Score b p-Value c ID d
Methylmalonyl-CoA mutase deficiency (N = 1)
Propionylcarnitine [↑] (+) 102.2 * 1.91 × 10−3 1
Methylmalonylcarnitine [↑] (+) 2201.5 * 1.51 × 10−2 1
Methylcitric acid (1) [↑] (−) 1204.5 * 1.12 × 10−3 1
Methylcitric acid (2) [↑] (−) 4.5 * 3.41 × 10−5 1
Methylmalonic acid [↑] (−) 221.5 * 2.81 × 10−3 1
Mevalonic aciduria (N = 1)
Mevalonic acid [↑] (−) 0.9 9.00 × 10−2 4
Mevalonolactone [↑] (−) NF NF -
Organic cation transporter 2 deficiency (N = 1)
Carnitine [↓] (+) −2.2 * 2.39 × 10−3 1
Ornithine aminotransferase (N = 1)
3-Amino-2-piperidone [↑] (+) 29.5 * 7.96 × 10−4 4
Guanidinoacetic acid [↓] (+) −1.2 * 2.60 × 10−4 1
Ornithine [↑] (+) 31.7 * 2.51 × 10−3 1
Ornithine transcarbamylase deficiency (N = 2)
Citrulline [↓] (+) 1.8 */1.8 * 2.09 × 10−3/5.18 × 10−6 1
Glutamine + Glutamic acid [↑] (+) 1.5 * 7.07 × 10−5 1
Orotic acid [↑] (−) 0.2/NF 0.394/NF 4
Uridine [↑] (−) 7.3 */4.8 * 2.36 × 10−6/7.07 × 10−3 1
Phenylketonuria (N = 3)
2-Hydroxyphenylacetic acid [↑] (−) NF NF 1
Glutamylphenylalanine [↑] (+) 64.3 */31.5 */NF 1.30 × 10−3/1.44 × 10−2/NF 1
N-Acetylphenylalanine [↑] (−) 42.7 *–136.2 * 3.33 × 10−2–1.35 × 10−3 1
N-Lactoyl-phenylalanine [↑] (−) 39.9 */41.6 * 2.77 × 10−2–9.96 × 10−3 1
Phenylacetic acid [↑] (−) 1.7 *–6.0 * 1.01 × 10−2–3.03 × 10−5 1
Phenylalanine [↑] (+) 29.0 *–88.1 * 9.42 × 10−3–<1.1 × 10−16 1
Phenylalanylphenylalanine [↑] (+) 10.3 */33.3 */NF 1.10 × 10−2/1.21 × 10−2 /NF 1
Phenyllactic acid [↑] (−) 71.8 */125.4 */NF 3.33 × 10−3/1.04 × 10−2/NF 1
Phenylpyruvic acid [↑] (−) −0.8 */−0.1/NF 8.01 × 10−3/7.57 × 10−1/NF 1
alpha-N-Phenylacetylglutamine [↑] (−) 1.4 *–4.2 * 3.64 × 10−4–3.20 × 10−6 1
Propionic acidemia (N = 1)
2-Methyl-3-hydroxybutyric acid [↑] (−) NF NF -
3-Hydroxypropionic acid [↑] (−) NF NF -
3-Hydroxyvaleric acid [↑] (−) NF NF -
3-Ketovaleric acid [↑] (−) NF NF -
Propionylcarnitine [↑] (+) 137.4 * 1.13 × 10−4 1
Glycine [↑] (+) 14.5 * 5.46 × 10−3 1
Methylcitric acid (1) [↑] (−) 1001.9 * 6.26 × 10−3 1
Methylcitric acid (2) [↑] (−) 576.1 * 2.84 × 10−3 1
Propionylglycine [↑] (−) 950.7 * 1.27 × 10−3 2b
Tiglylglycine [↑] (−) NF e NF -
Thymidine phosphorylase deficiency (N = 1)
Deoxyuridine [↑] (−) 370.9 * 6.97 × 10−4 1
Thymidine [↑] (−) 64.6 * 2.20 × 10−3 1
Thymine [↑] (−) NF NF -
Uracil [↑] (−) −0.9 1.12 × 10−1 1
Tyrosinemia I (N = 2)
4-Hydroxyphenylacetic acid [↑] (−) 140.8 */NF 6.53 × 10−3/NF 1
4-Hydroxyphenyllactic acid [↑] (−) 389.5 */1013.8 * 6.02 × 10−3/3.39 × 10−3 1
4-Hydroxyphenylpyruvic acid [↑] (−) 4.2 */0.6 7.29 × 10−7/5.69 × 10−1 1
N-Acetyltyrosine [↑] (−) 32.4 */96.0 * 9.55 × 10−3/5.73 × 10−3 1
Phenylpyruvic acid [↑] (+) 113.8 */NF 4.09 × 10−3/NF 1
Succinylacetone [↑] (−) NF NF -
Tyrosine [↑] (+) 18.8 */36.9 * 4.82 × 10−3/1.88 × 10−4 1
Very long chain acyl-CoA dehydrogenase deficiency (N = 1)
Tetradecanoylcarnitine [↑] (+) 36.6 * 6.31 × 10−3 2b
Tetradecenoylcarnitine [↑] (+) 85.5 * 1.97 × 10−2 2b
Tetradecadienoylcartinine [↑] (+) 42.9 * 1.38 × 10−2 2b
Hexadecanoylcarnitine [↑] (+) 6.8 * 9.69 × 10−3 1
Octadecanoylcarnitine [↑] (+) 2.7 * 1.06 × 10−2 1
Oleoylcarnitine [↑] (+) 5.9 * 4.26 × 10−5 2b
Carnitine palmitoyltransferase II (N = 2)
Hexadecanoylcarnitine [↑] (+) 9.6 */21.6 * 9.01 × 10−3/2.28 × 10−2 1
Octadecanoylcarnitine [↑] (+) 12.6 */33.4 * 1.22 × 10−2/2.70 × 10−2 1
Oleoylcarnitine [↑] (+) 7.2 */21.4 * 4.10 × 10−3/4.06 × 10−2 2b
Sebacic acid [↑] (−) 0.2/−0.3 7.59 × 10−1/4.69 × 10−1 4
Suberic acid [↑] (−) 0.7/−0.1 3.78 × 10−1/7.82 × 10−1 4
a: For each IEM, the number of patients analyzed is indicated between brackets. For each biomarker the expected
change (↑ = elevated, ↓ = decreased) is indicated between square brackets and the ion mode (+ = ESI-(+), − = ESI-(−),
+/− = ESI-(+) and ESI-(−)) between brackets for each z-score reported; b: Average z-score of a metabolite in patients,
* indicates Welch’s t-test on the triplicates yields a p-value < 0.05, slash indicates separate values of two patients.
Two dashes indicate the range of z-scores when the number of patients ≥ 3, NF = marker not detected or annotated;
c: Slash indicates separate p-values of two patients. Two dashes indicate the range of the p-values when the number
of patients ≥ 3, NF = marker not detected/annotated; d: Confidence level of metabolite annotation according to MSI
initiative reporting standard [17]; e: Marker detected in LC-MS analysis, not peak-picked by Progenesis QI.
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3. Discussion
Mass spectrometry analytics has matured in recent decades. As a result, metabolomic studies have
grown more precise and comprehensive, now allowing the identification of hundreds to thousands of
unique metabolites in the analysis of a single biol gical sample [23]. The current study concerns a novel
platform for u targeted metabolomics in diagnosing IEM based on semi-automatic sample preparation
combined with pentafluorophenylpropyl phase-based (Kinetex F5) UHPLC coupled to Orbitrap-MS.
The individual capabilities of each of these two analytical techniques will work synergistically and
enable analysis of low-abundance components in complex samples and separation of isobaric and
isomeric species. As an example, we showed the clear separation of the isomers isohexanoylglycine
and hexanoylglycine and the isomers N-acetylleucine and N-acetylisoleucine (Figure 2). To minimize
the chance of false positive and false negative results we used the Q Exactive Plus at a resolution of
140,000 (full half-maximum width at 200 m/z). The exceptional specificity of a resolution of 140,000
is of great impor ance. As w showed, 64% of the isobaric pairs that need resolution higher than
40,000 will be separated at a resolut on 140,000. Furthermore, the within ba ch quality control data
show that, even with this ultra-high resolution, peak areas can be determined accurately. Last but
not least, we used a semi-automatic sample preparation procedure. To the best of our knowledge,
fully or semi-automated sample preparation procedures have not been used in metabolomics studies
to diagnose IEM. Other methods have used manual protein precipitation and centrifugation [8–11].
Semi-automated sample processing potentially increases laboratory efficiency, reduces user errors and
increases reproducibility. It must be noted that we did not investigate performance of semi-automated
sample preparation in co arison to ma ual sample processing, but, from a practical point of
view, automation did facilitate integration of sampling handling into the lab information system.
An additional advantage of the 96-well Phree filter plates that we employed, is selective binding of
phospholipids, which, if not removed, may cause ion suppression [24].
We have evaluated our method by testing 53 patient samples corresponding to 33 different
IEM and achieved a correct diagnosis in 90% of the cases. Disorders from the following
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disease groups were included: aminoacidopathies, urea cycle disorders, organic acidurias, fatty
acid oxidation defects, purine and pyrimidine disorders and peroxisomal disorders. For an
additional IEM disease group—lysosomal storage disorders—the utility of clinical testing using
metabolomics has not been not been reported before. We demonstrate that our metabolomics
platform is able to detect mannosyl-β1,4-N-acetylglucosamine (GlcNAc-Man), the current biomarker
for β-mannosidase deficiency. Preliminary experiments on oligosaccharidoses showed that biomarkers
for aspartylglucosaminuria and α-mannosidosis were also easily detectable (data not shown).
A limitation of our platform was encountered in the raw data processing steps using Progenesis
QI. Using a mass resolution of 140,000 allows the determination of the fine isotope pattern (N, O and S
atoms) of molecules with m/z < 500, which helps to identify biomarkers by restricting the number of
possible annotations. Unfortunately, Progenesis QI was unable to extract the fine isotope patterns,
which were indeed correctly recorded by the orbitrap MS. Consequently, we could not use the fine
isotope patterns to determine isotope similarity scores. For the annotated compounds, the isotope
similarity score was always >85%, which we considered acceptable. Another drawback of Progenesis
QI is that integration of picked peaks cannot be edited, e.g., to split isobaric compounds, which the
algorithm integrated as a single peak, or to manually add peaks, which were missed by the peak
detection algorithm. This resulted in missed annotations and the inability to report some isomers,
which were, in fact, present in the raw data. Better procedures for peak-picking and deconvolution of
adducts and isotope signals are required to optimize metabolite identification (see below).
Applications of untargeted metabolomics platforms to clinical testing in the field of IEM are scarce.
Those platforms that used plasma samples include the approach reported by Miller et al., using GC-MS
and LC-high resolution MS run in parallel [8], an LC-QTOF/MS method described by Coene et al. [9],
and a direct infusion-Orbitrap-MS method reported by Haijes et al. [11]. Comparison of method
performances is complicated, since many variations exist between the different approaches. Retention
time stability observed on our PFPP column was ≤ 1.1% within batch and <2% between batches, which
is very similar to the values (<1% within run and <2% between run) reported by Coene et al. [9] for
the commonly used C18 UHPLC and indicates that very stable chromatography can be achieved on
PFPP-based columns. Since the aforementioned metabolomics approaches rely on relative perturbations
in metabolite levels, peak area detection must be reproducible across different samples. For the 17
stable isotope-labeled standards added to the samples, the within-batch median peak area CVs were
7–19% (data from all plasma samples included in a batch). These values compare well to the median
CV values determined in a similar manner by Haijes et al. [11]: 16–21%. Coene et al. [9] reported a
median CV of <20% for approximately 20 metabolites in their QC samples. We found that, in our
method, the median within-batch CV values of peak areas of metabolites detected in the QC sample are
well below 20% across the chromatogram (Figure 3). Only in the last two minutes of the chromatogram
peak area CV values were larger, which may be explained by the fact that late-eluting compounds
are apolar metabolites, e.g., long chain acylcarnitines, which are present at very low concentrations
(<0.1 µmol/L) in the QC sample with limited solubility in the final diluent (water:methanol 95:5%
+ 0.5% v/v formic acid). The resulting fluctuations in metabolite recovery may be a major cause of
the relatively high variation observed. Since these IEM screening methods investigate metabolite
abnormalities within-batch, variation in peak areas between different experimental batches is less
of an issue. Still, a stable platform is desirable and between-batch variation in peak areas should be
monitored. Median between-batch variation of all standards in all samples was acceptable (27%).
A challenge in the use of untargeted metabolomics platforms to screen for IEM is the lack of
adequate determination of some clinically relevant metabolites. Using our platform, homogentisic
acid and mevalonic acid levels were not increased in an alkaptonuria sample and a hyper-IgD
syndrome sample, respectively, and this resulted in failure to establish the diagnoses in these two
cases. Similarly, a normal glutamine level was observed in one CPS I sample, which impeded correct
diagnosis. Several other metabolites were not annotated or had normal values (Table 1), e.g., orotic
acid in two OTC samples, but in these cases the correct diagnosis could still be established, because
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other metabolites had abnormal levels. Similar findings have been reported by other researchers.
The platform described by Miller et al. [8] correctly diagnosed 20 out of the 21 IEM tested. Their method
did not identify methylmalonic acid, tetradecenoylcarnitine (C14:1), and guanidinoacetic acid, but only
in the latter case the diagnosis of guanidinoacetate methyltransferase (GAMT) deficiency was missed.
Coene et al. [9] correctly identified 42 out of 46 diagnoses and could not diagnose argininosuccinate
lyase deficiency, dimethylglycine dehydrogenase deficiency and GAMT deficiency, because abnormal
values of argininosuccinic acid, dimethylglycine and guanidinoacetic acid were not annotated. A
possible explanation for the inability to detect argininosuccinic acid was the lack of retention by C18
chromatography [9]. In our method, using PFPP-based chromatography, argininosuccinic acid was
retained and correctly annotated in all three cases tested. Finally, the DI-HRMS method reported
by Haijes et al. [11] could make a precise diagnosis in 19 of the 21 IEM tested in plasma but did not
identify methylenetetrahydrofolate reductase deficiency and carnitine palmitoyltransferase I deficiency.
Several causes may explain the lack of abnormal test results and the failure to establish a diagnosis.
First, due to the rarity of IEM, some samples used in our method evaluation, as well as in studies
by others [8–11], were taken from patients who had already received specific treatment for their
condition, which has resulted in less pronounced or even normalized disease-specific biochemical
abnormalities. It is to be expected that undiagnosed and untreated patients will show larger deviations
in metabolite patterns, which will improve diagnostic accuracy. Prospective studies are required to
demonstrate the full capability of untargeted metabolomics platforms in screening for IEM. Second,
technical limitations in the used platforms, such as sample preparation, chromatography, raw data
processing and data analysis, may hinder correct test results for certain metabolites [8,9,11]. We
expect that developments in data analysis will lead to improvement in the methodology. In raw data
processing, for example, better procedures for peak-picking and deconvolution of adducts and isotope
signals will improve metabolite identification (our data and [9]). The application of comprehensive
databases containing all (possible) biomarkers of IEM, informative metabolite ratios and algorithms
assisting in recognition of characteristic metabolite patterns are required to further optimize diagnostic
performance. As an example, we show that expanding the number of biomarkers for hyperargininemia
facilitates its diagnosis.
It is worth reiterating that comparison of the performance of the different methods reported for
IEM screening by untargeted metabolomics platforms is complicated, since many variations exist
between the different studies, e.g., different IEM were tested and for each disorder distinct samples with
different degrees of metabolite abnormalities were used. Appropriate testing of method performance
should be performed by sample exchange programs or External Quality Assurance schemes.
In this study, we describe a novel metabolomics method applying a semi-automatic sample
preparation procedure combined with UHPLC-Orbitrap-MS. Our metabolomics platform differentiates
signatures of many different IEM from that of controls. The use of metabolomics in the field of IEM
diagnostics is still in its childhood and likely has not reached its full potential yet. Nevertheless,
our results and those of others [8,9,11] show that the number of IEMs detected by metabolomics
increases. Progress in automation, like we applied in our novel method, and data analyses, will make
diagnostics of IEM faster and cheaper. We envision that in the near future the current approach to
diagnose IEM, with numerous targeted tests, will be replaced by untargeted metabolomics methods.
Noticeably, we, as well as others [8,9,11], show the potential of metabolomics in IEM diagnostics, but
in none of these reports full analytical and clinical validation has been performed, while this is a
requirement before application in the clinic. In addition to the potential of screening for known IEMs,
untargeted metabolomics platforms allow the identification of new biomarkers, useful to establish
diagnoses or to use as a surrogate marker for disease outcome [9,25,26]. Finally, metabolomics
provides a comprehensive biochemical phenotype that facilitates interpretation of possible biochemical
consequences of variants of unknown significance identified in whole exome sequencing or whole
genome sequencing [9,11,27].
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4. Materials and Methods
4.1. Reagents and Chemicals
Acetonitrile (hypergrade) and formic acid were from Merck (Amsterdam, The Netherlands) and
UPLC water and methanol from Biosolve (Valkenswaard, The Netherlands). Internal and external
standards (mostly isotope labeled) were selected on the basis of two criteria. First, compounds
were selected to represent a number of different compound classes, i.e., amino acids, organic acids,
acylcarnitines, purines and pyrimidines and a bile acid. Second, from these different compound classes,
compounds were selected to have retention times across the chromatogram. An internal standards
mixture was prepared containing 600 µmol/L L-phenylalanine (ring-[D5], 98%), 300 µmol/L thymidine
(methyl-[13C], 98%), 300 µmol/L uracil (1,3-[15N], 98%), 500 µmol/L isoleucine ([D10], 98%), 225 µmol/L
ornithine (3,3,4,4,5,5–[D6], 98%), 230µmol/L tyrosine (ring-[D4], 98%) (Cambridge Isotopes Laboratories,
Tewksbury, MA, USA), 85 µmol/L 5-bromo-DL-tryptophan, 300 µmol/L 3,3-dimethylglutaric acid,
44 µmol/L glycochenodeoxycholic-2,2,4,4-[D4] acid (Sigma Aldrich, Zwijndrecht, The Netherlands),
and 285 µmol/L [D3]-carnitine (H. ten Brink, Amsterdam UMC, Amsterdam, The Netherlands). An
external standards mixture consisted of 100 µmol/L methylmalonic acid (methyl-[D3], 98%), 207 µmol/L
uridine (ribose-5,5-[D2], 98%), 670 µmol/L L-valine ([D8], 98%) (Cambridge Isotopes Laboratories,
Tewksbury, MA, USA), 45 µmol/L [D2]-acetylcarnitine, 21 µmol/L [D3]-hexanoylcarnitine, 19 µmol/L
[D3]-tetradecanoylcarnitine, 6 µmol/L [D3]-hexadecanoylcarnitine (H. ten Brink, Amsterdam UMC,
Amsterdam, The Netherlands).
Standard mixtures used for external calibration of the Q Exactive Plus were Calmix positive and
Calmix negative, for the positive and negative ion mode, respectively (Thermo Fisher Scientific, Breda,
The Netherlands). Additionally, an in-house ‘Metabolic Laboratory’ negative ion mode calibration mix
was made to ensure mass accuracy for ions with a m/z < 262, containing 500 µmol/L L-phenylalanine,
500 µmol/L methylmalonic acid, 150 µmol/L taurocholic acid and 330 µmol/L uridine (Sigma Aldrich,
Zwijndrecht, The Netherlands). The lock mass solution consisted of 400 mg/L caffeine and 400 mg/L
5-bromo-uracil (Sigma Aldrich, Zwijndrecht, The Netherlands). Custom calibration mix negative ion
mode was made by combining 30 µL lock mass solution, 30 µL Metabolic Laboratory negative ion
mode calibration mix and 300 µL Calmix negative. The ClinCal amino acid calibrator from Recipe
(Munich, Germany) was used as a QC sample.
4.2. Sample Selection
Our metabolomics workflow was tested on a range of 33 distinct IEM. In total, 53 plasma samples
from 33 known IEM patients (1–4 samples per IEM) were analyzed. IEM diagnoses were previously
confirmed by enzyme and/or molecular testing when appropriate. Control samples were obtained
from remaining material of patients, which screened negative for all known IEM. Heparin blood
samples of both groups were drawn for routine metabolic screening or therapy monitoring without
applying a specific protocol on collection of material (e.g., time, fasting/dietary status, treatment).
In agreement with national legislation and institutional guidelines, all patients or their guardians
approved the possible anonymous use of the remainder of their samples for method validation
purposes. The study was conducted in accordance with the Declaration of Helsinki. Samples were
stored in a digital-alarm-controlled freezer at −20 ◦C before analysis for a period ranging from 2 weeks
to 14 years. Samples were analyzed in eight experimental runs (batches), including 2–14 IEM samples
and 25–38 controls (random age and gender) per batch.
4.3. Semi-Automated Sample Preparation Procedure
Semi-automated sample preparation was performed on a Hamilton Robotics ML-STAR eight
channel pipetting robot equipped with a camera, iSwap robotic hand, an orbital shaker, an orbital
heater/shaker and a vacuum station (Bonaduz, Switzerland) according to the following procedure.
All samples were thawed at room temperature for 20–30 min and mixed by vortexing. For each sample
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a 200 µL aliquot was pipetted into a 1.5 mL polypropylene tube with a unique 2D-barcode containing
the sample identifier. Subsequently, all samples were centrifuged at 13,000 rpm for 5 min at 4 ◦C.
An input file for the pipetting robot was created, containing the name of each sample, the
corresponding 2D barcode and whether the sample should be treated as a patient or non-patient sample
(e.g., control, blank). Thereafter, the 2D barcodes of the samples in the sample trays were scanned.
If the order in the sample trays matched the order on the worklist, sample preparation started. First
the vacuum station was assembled by iSwap. Then, 450 µL acetonitrile containing 1% formic acid
was added to each well of a Phree 96 well plate (Phenomenex, Maarsen, The Netherlands), which was
placed on the shaker. Subsequently 20 µL of internal standards mix was added, followed by 50 µL of
sample. For each sample marked as a patient, this was done in triplicate (three separate wells). The 96
well plate was shaken during 2 min at 1000 rpm. After shaking, the iSwap moved the Phree plate to
the vacuum station for filtration. A delta pressure of 600 mbar was applied for 5 min to separate the
metabolite extract from the protein precipitate. After filtration, the iSwap moved the Phree plate back
to the shaker where 500 µL methanol + 1% formic acid was added to each well. The plate was shaken
for 2 min at 800 rpm and moved back to the vacuum station for filtration (delta pressure 600 mbar
for 5 min) to facilitate extraction of remaining metabolites. The collected filtrate was evaporated to
dryness at 60 ◦C on a Porvair Ultravap (Porvair Sciences Limited, Norfolk, UK). The plate was then
placed on the heated shaker position of the pipetting robot and 200 µL water/methanol (95:5) with
0.5% formic acid was added to each well, followed by shaking at 800 rpm for 2 min. Subsequently,
20 µL external standards mix was added to each well of a 350 µL microtiter plate and 130 µL of each
sample extract was transferred to the microtiter plate. After shaking for 2 min at 200 rpm, the plate
was sealed with a pre-slit PTFE cover (Thermo Scientific, Breda, The Netherlands) and placed in the
autosampler of a Dionex Ultimate 3000 UHPLC chromatographic system (Thermo Fisher Scientific,
Breda, The Netherlands). Sample preparation and the start of the UHPLC-Orbitrap-MS(/MS) analysis
always took place on the same day.
4.4. UHPLC-Orbitrap-MS(/MS) Analysis
UHPLC-MS(/MS) analysis was performed using a Dionex Ultimate 3000 UHPLC chromatographic
system combined with a Q Exactive Plus mass spectrometer fitted with a heated electrospray source
operated in the positive or negative ion mode. The software interface was Xcalibur 4.0.27.42, SII 1.3
and MSTune 2.8 SP 1 (Thermo Fisher Scientific, Breda, The Netherlands).
UHPLC separation was performed on a Kinetex F5 2.6 µm 2.1 mm × 150 mm column equipped
with an F5 guard column (Phenomenex, Maarsen, The Netherlands). The column was kept at 20 ±
0.1 ◦C during analysis. Mobile phases were A: 100% water, 0.5% formic acid also containing 40 µg/L
caffeine and 40 µg/L 5-bromo-uracil as lock mass compounds, and B: 100% ACN and 1.0% formic
acid. The injection volume for all separations was 3 µL. Chromatographic elution was achieved under
gradient conditions with a flow rate of 400 µL/min. Elution started with an isocratic step of 1.03 min at
0% B, followed by a linear gradient from 0% to 25% B (1.03–2.60 min), 25% to 35% B (2.60–5.70 min),
and 35% to 95% B (5.70–7.78 min). These conditions were maintained for 3.59 min before returning to
0% B in 0.03 min and equilibration at start conditions for 3.66 min. The total runtime was 15 min.
The Q Exactive Plus mass spectrometer was operated with a capillary voltage of -3.50 kV in the
negative ionization mode and 3.50 kV in the positive ionization mode. The capillary temperature was
set at 380 ◦C, and auxiliary gas temperature at 300 ◦C. The sheath gas pressure, auxiliary gas pressure
and sweep gas flow rate were set at 60, 20, and three arbitrary units, respectively, with nitrogen gas.
Detection was achieved in both ionization modes from 70 to 1050 m/z. To set the correct pre-scan
frequency, chromatographic peak width (FWHM) was set at 3 s in all modes. In full scan mode, the
resolution of the analyzer was set at 140,000 (m/∆m, FWHM @ 200 m/z). The maximum inject time was
set at 100 ms. AGC-target was set to 3E6. In Full scan - ddMS2 mode: The survey scan was obtained
with a resolution of 70.000 (m/∆m, FWHM @ 200 m/z). Maximum inject time was set to 100 ms and
AGC-target was set at 3E6. MS/MS scans were acquired with a resolution of 17,500 (m/∆m, FWHM @
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200 m/z) with a maximum inject time of 35 ms. ddMS settings were as follows: minimum AGC Target:
5.00e3, intensity threshold: 1.4E5, apex trigger: 2 to 4 s and dynamic exclusion: 2.5 s. The AGC-target
was set at 2E4. The isolation window was 1.5 m/z.
Three types of ddMS/MS experiments were performed on a pooled sample containing an aliquot
of all patient samples present in the analytical run:
1. Inclusion list set at on (do not pick others)
2. Inclusion list set at on (do pick others), exclusion list set at on
3. Inclusion list set at off, exclusion list set at on
In these experiments, the 12 most abundant ions were fragmented (TopN 12) with an NCE value
of 20%, 35% and 50%, unless a specific known optimal NCE value was specified in the inclusion list.
These optimal NCE values were taken from the mzCloud website [28]. The inclusion list consisted of
743 small metabolites, many of which were known markers of IEM. The positive and negative ion
mode had separate inclusion lists. The ESI(+) inclusion list contained m/z-values of the [M+H] adducts
of all biomarkers. The ESI(−) inclusion list contained m/z-values of the [M−H] adducts.
Prior to each analytical run, the mass spectrometer system performance was evaluated and
calibrated using Calmix positive for the positive ion mode using the predefined evaluation and
calibration of the manufacturer, including mass-calibration on N-tert-butylamine, caffeine and MRFA to
ensure mass accuracy for ions <200 m/z. For the negative ion mode Calmix negative was used. System
evalution and calibration were performed using the predefined evaluation and calibration options
of the manufacturer. Subsequently, a custom mass-calibration was performed with our in-house
‘Metabolic Laboratory’ negative ion mode calibration mix to ensure mass accuracy for ions <262 m/z.
During analysis lock-mass calibration was used to maximize mass accuracy. Caffeine and
5-bromo-uracil were used as lock masses, for the positive and negative ion mode, respectively.
Generation of the LC-MS sequence list was integrated in the semi-automatic sample preparation.
This enabled random injection order of the patient and control samples. Each sequence of
UHPLC-Orbitrap-MS analyses was started with the positive ion mode. The UHPLC start-up method
was followed by four injections of the blank sample (water) to stabilize the chromatographic column.
Subsequently, the QC sample was measured. Thereafter, the patient and control samples were analyzed
in a random order, with an analysis of the QC sample after every 10th run. When all patient and control
samples were measured, DDA-MS/MS analyses were performed. Then, all samples were measured in
the negative ion mode. The negative ion mode started with four injections of the blank. The same
procedure was followed, as described for the positive ion mode. The DDA-MS/MS analyses in the
negative ion mode were followed by a shutdown program.
4.5. Quality Control
4.5.1. Retention Time Stability
Retention time of all standards was monitored in all plasma-based samples. The following
tolerances were applied for all standards. The maximum allowed within-batch RT variation was set at
<1.5% and the maximum allowed between batch RT variation was set at <2%.
4.5.2. Within Batch Peak Area Variation
Peak areas of the internal and external standards in all plasma-based samples were
integrated using Xcalibur 4.0 and manually reviewed in the Quan-browser module of
Xcalibur. [D5]-phenylalanine, 1,3-[15N]-uracil, [D10]-isoleucine, [D6]-ornithine, [D4]-tyrosine,
5-bromo-DL-tryptophan, 3,3-dimethylglutaric acid, [D3]-carnitine, [D2]-uridine, [D8]-valine,
[D2]-acetylcarnitine, [D3]-hexanoylcarnitine, [D3]-tetradecanoylcarnitine, [D3]-hexadecanoylcarnitine
were monitored in positive ion mode and [D5]-phenylalanine, [13C]-thymidine, 1,3-[15N]-uracil,
[D4]-tyrosine, 5-bromo-DL-tryptophan, 3,3-dimethylglutaric acid, [D4]-glycochenodeoxycholic acid,
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[D3]-methylmalonic acid, [D2]-uridine, and [D8]-valine were monitored in the negative ion mode. The
within-run CV of the peak area of all standards was not allowed to exceed 30%.
Additionally, in the QC sample, the CVs in the peak area of all annotated endogenous metabolites
were calculated. Then the calculated CVs were binned on retention time (increments of 1.0 min) and
subsequently the median of each bin was taken.
4.5.3. Between-Batch Peak Area Variation
The median peak area of all internal and external standards within the measured QC samples was
monitored. The between-batch variation was not allowed to exceed 30%.
4.5.4. Data Processing
The raw data were imported into Progenesis QI v2.4 (Newcastle-upon-Tyne, UK). Progenesis QI
deals with alignment of the chromatograms, normalization, deisotoping, adduct deconvolution, peak
picking and peak annotation. All settings used within Progenesis QI can be found in the supplementary
materials (S7). Progenesis QI, builds an aggregate of the features detected in all samples included
in a batch. Any feature detected in one sample in a batch will be detected in all samples in that
batch. Each batch contained different samples of patients with varying IEM. Therefore, the number of
annotated metabolites varied per batch due to the presence of abnormal metabolites only detected
in patient samples. Initially, HMDB 4.0 was used for compound annotation [29–32]. Compound
ions were annotated by matching the retention time (max. ∆ RT: 0.15 min), isotope pattern similarity
(>85%) and m/z-value of a feature (max. ∆ ppm: 3) with an in-house database containing metabolites
which are known biomarkers for IEM. At the time of writing, this database contains 757 entries of
endogenous metabolites, of which 408 have a retention time validated by standards or plasma samples
of IEM patients with established metabolite abnormalities. Known co-eluting isomeric compounds
share one entry in the database. A selection of 339 metabolites relevant to IEM screening was used to
annotate compound ions for routine diagnostic purposes (list available on request). MS/MS spectra
were included when available to increase the confidence of the annotation. Here, the dot product score
must be larger than 0.60. The confidence level of metabolite annotation was established according to
the MSI initiative reporting standard [17].
After these processing steps, we obtained for every batch a matrix containing abundancies where
every element corresponded to a sample and feature. Note that some abundancies are the summation
of the detected adducts and their isotopes. This matrix, together with qualitative data (e.g., ppm error,
isotopic pattern and annotation), was exported as a csv-file and processed by our data pipeline. Within
the pipeline, z-scores were calculated for each metabolite by using 15 control samples originating
from the same batch as the patient. The z-score was defined as the number of standard deviations a
measured value was above or below the mean of the control group. Matching of the controls with the
patient was performed on age and sex. First, the controls with the same sex were selected, then we
determined the most age-related controls and defined an age cut-off based on the following equation,
where age is in years:
agepatient
0.95 − 0.5 ≤ agecontrol ≤ agepatient1.05 + 0.5
These cut-offs have the tendency to be less strict for increasing age and have a small bias towards
older reference samples. When there were less than 15 controls fulfilling these conditions, additional
controls were chosen by their similarity in age (which might include the opposite sex). Note that,
because of the limited number of controls in a batch, this matching was also limited.
Technical triplicates of patient samples allowed us to gain insight into the technical variability of
every metabolite. Excessive technical variability was detected by using the Welch’s t-test, which was
considered appropriate since the variance of the triplicate differed from the variance of the reference
population (the 15 controls). We expected triplicates with a relatively large variance but distant average
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from the reference average to have low p-values (acceptable measurement). Increasing the variance
of the triplicate while fixing the distance to the reference average should lead to increasing p-values
(unacceptable measurement). For p-value >0.05, we considered that technical variability of the triplicate
was too large to rely on the inferred z-score (average of the triplicates).
5. Conclusions
In this paper we describe a novel untargeted metabolomics platform for screening IEM
combining semi-automatic sample preparation with pentafluorophenylpropyl phase (PFPP)-based
UHPLC-Orbitrap-MS. We demonstrate robust performance and show that our method differentiates
metabolite patterns of many different IEM from those of controls.
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-1989/9/12/289/s1,
Table S1: Within-batch variation in retention time, Table S2: Between-batch variation in retention time, Table S3:
Within-batch variation in peak area, Table S4: Between-batch variation in peak area, Figure S5: Peak area variation
of all metabolites annotated in the QC sample, Figure S6: Separation of the isomeric pairs isoleucine/leucine and
betaine/valine, Table S7: Progenesis QI settings, MS Excel file S8: Information on annotated features used for
determination of the variation in peak area.
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